Palliative radiotherapy as treatment for non‐resectable soft tissue sarcomas in the dog – a report of 15 cases

Plavec, Tanja; Kessler, Martin; Kandel, Bishnu Prasad; Schwietzer, A.; Roleff, S.

doi:10.1111/j.1476-5810.2006.00097.x

Cited by 26 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ORR of 67% from the protocol assessed herein was comparable to other protocols. Other palliative protocols, the majority of which involve three to four fractions of 6 to 8Gy given once weekly, have ORRs ranging from 6.6 to 93% . Since most of these results relate to pain relief from appendicular osteosarcoma, these response data are not an ideal comparison.…”

Section: Discussionmentioning

confidence: 99%

“…alliative radiation therapy is typically reserved for patients with incurable tumors causing pain, discomfort, or general decrease in quality of life. Palliation was used originally for bone tumors, but it has also been used for other sarcomas, melanoma, and carcinomas . Many protocols involve 8Gy fractions given once weekly for 2–4 weeks .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RESPONSE RATE AND DURATION ASSOCIATED WITH A 4GY 5 FRACTION PALLIATIVE RADIATION PROTOCOL

McDonald¹,

Looper²,

Greene

2011

Vet Radiology Ultrasound

View full text Add to dashboard Cite

The purpose of this retrospective study was to determine if 4Gy fractions over 5 consecutive days is an effective and safe palliative radiation protocol for dogs and cats. Eighty patients (22 cats, 58 dogs) with complete follow-up information were evaluated. Overall response rate (ORR) for all patients was 67%. Median progression free survival (MPFS) was 3.3 months and median survival (MST) was 4.2 months. Primary bone tumors were the most common tumors treated. The ORR for primary bone tumors was 66.6%, the MPFS was 3.5 months, and MST was 3 months. The most common tumor treated in cats was oral squamous cell carcinoma and ORR was 54.5 %, the MPFS was 1.8 months, and MST was 3 months. Soft tissue sarcomas were the second most common tumor treated in dogs (10). ORR was 80% and the two other patients had stable disease. MPFS was 5.7 months and MST was 7.9 months. Overall rate of toxicity was 18.4% in 65 sites that were evaluated for toxicity. Acute toxicities were all grade I or II and occurred in 16.9 % of patients evaluated. All late toxicity was grade I alopecia and leukotrichia. There appears to be a comparable response rate for this palliative protocol as compared to others historically. This response was seen over a wide range of tumors. We also documented a low toxicity profile in a shorter overall treatment time, making this protocol more attractive for some clients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

RESPONSE RATE AND DURATION ASSOCIATED WITH A 4GY 5 FRACTION PALLIATIVE RADIATION PROTOCOL

McDonald¹,

Looper²,

Greene

2011

Vet Radiology Ultrasound

View full text Add to dashboard Cite

show abstract

“…External beam radiation is a versatile therapy and can be used in the palliative setting for both tumour control and analgesia (Brearley and others 1999, Ramirez and others 1999, Bregazzi and others 2001, Moore 2002, Farrelly and McEntee 2003, Mayer and Grier 2006, Plavec and others 2006, Coomer and others 2009, Poirier and others 2013, Fujiwara-Igarashi and others 2014, Kung and others 2014) (Figs 4, 5). At the time of writing, there are six veterinary radiation facilities with linear accelerators in the UK (Box 3).…”

Section: Radiotherapymentioning

confidence: 99%

Palliative care in small animal oncology

Mason¹

2016

In Practice

View full text Add to dashboard Cite

Cancer is a common diagnosis in companion animals and, increasingly, clients choose to pursue treatment for their pets. Veterinary oncology is a rapidly growing field and diagnostic and treatment options for animals with cancer are constantly improving and becoming more widely available. Treatment outcomes can be good, but in many cases definitive treatment is not an option and palliative treatment is necessary. This article explores the palliative care of dogs and cats that have been diagnosed with cancer and summarises the various treatment options, with a particular focus on quality of life and the role of communication in the decision-making process.

show abstract

“…For example, some studies include visceral STSs, 4,34,48 and some studies include histiocytic sarcomas, 25,48 leiomyosarcomas, 48 haemangiosarcomas, 18 and synovial cell sarcomas. 45,48 This confounds evaluation of prognostic factors because most of these neoplasms probably behave more aggressively than conventional cutaneous and subcutaneous STSs. Finally, several studies have dissimilarity between patients in terms of natural disease history (eg, length of time that a tumor was present, inclusion of patients with recurrent tumors or detectable metastasis); 5,23,46 these may have failed to detect true differences in prognosis.…”

Section: Limitations Of Canine Sts Prognostic Studiesmentioning

confidence: 99%

Prognostic Factors for Cutaneous and Subcutaneous Soft Tissue Sarcomas in Dogs

McSporran²,

et al. 2010

View full text Add to dashboard Cite

Soft tissue sarcomas (STSs) develop from mesenchymal cells of soft tissues, and they commonly occur in the skin and subcutis of the dog. Although phenotypically diverse with frequently controversial histogenesis, STSs are considered as a group because they have similar features microscopically and clinically. Following resection, local recurrence rates are low in general but vary according to histologic grade and completeness of surgical margins. Complete margins predict nonrecurrence. Even most grade I STSs with ''close'' margins will not recur, but propensity for recurrence increases with grade. The frequency of metastasis has not been accurately estimated, but it is believed to be rare for grade I STSs and most likely to occur with grade III STSs. However, metastasis does not necessarily equate with poor survival. High mitotic index is prognostic for reduced survival time. Further research is needed to determine more precise estimates for recurrence rates and survival as related to completeness of surgical margins and to delineate potential differences in metastatic rate and median survival time between grades. Other potential indicators of prognosis that presently require further investigation include histologic type, tumor dimension, location, invasiveness, stage, markers of cellular proliferation, and cytogenetic profiles. Common issues limiting prognostic factor evaluation include biases from retrospective studies, small sample sizes, poor verification of metastasis, inconsistent STS classification and use of nomenclature, difficulties in differentiating STS phenotype, and diversity of the study population (stage of disease and treatment status).

show abstract

Palliative radiotherapy as treatment for non‐resectable soft tissue sarcomas in the dog – a report of 15 cases

Cited by 26 publications

References 19 publications

RESPONSE RATE AND DURATION ASSOCIATED WITH A 4GY 5 FRACTION PALLIATIVE RADIATION PROTOCOL

RESPONSE RATE AND DURATION ASSOCIATED WITH A 4GY 5 FRACTION PALLIATIVE RADIATION PROTOCOL

Palliative care in small animal oncology

Prognostic Factors for Cutaneous and Subcutaneous Soft Tissue Sarcomas in Dogs

Contact Info

Product

Resources

About